213 related articles for article (PubMed ID: 9865734)
21. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants.
Nguyen KT; Liu B; Ueda K; Gottesman MM; Pastan I; Chin KV
Oncol Res; 1994; 6(2):71-7. PubMed ID: 7949467
[TBL] [Abstract][Full Text] [Related]
22. p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction.
Zhang D; Cao D; Russell R; Pizzorno G
Cancer Res; 2001 Sep; 61(18):6899-905. PubMed ID: 11559567
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors.
Heegaard AM; Xie Z; Young MF; Nielsen KL
J Cell Biochem; 2004 Oct; 93(3):463-75. PubMed ID: 15372625
[TBL] [Abstract][Full Text] [Related]
24. Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia.
Bae SK; Bae MH; Ahn MY; Son MJ; Lee YM; Bae MK; Lee OH; Park BC; Kim KW
Cancer Res; 1999 Dec; 59(23):5989-94. PubMed ID: 10606246
[TBL] [Abstract][Full Text] [Related]
25. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
[TBL] [Abstract][Full Text] [Related]
26. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
[TBL] [Abstract][Full Text] [Related]
27. Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene.
Harris LC; Remack JS; Houghton PJ; Brent TP
Cancer Res; 1996 May; 56(9):2029-32. PubMed ID: 8616846
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein.
Lee Y; Chen Y; Chang LS; Johnson LF
Exp Cell Res; 1997 Aug; 234(2):270-6. PubMed ID: 9260894
[TBL] [Abstract][Full Text] [Related]
29. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Wolverton JS; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
[TBL] [Abstract][Full Text] [Related]
30. Evidence for transcriptional control of human mdr1 gene expression by verapamil in multidrug-resistant leukemic cells.
Muller C; Goubin F; Ferrandis E; Cornil-Scharwtz I; Bailly JD; Bordier C; Bénard J; Sikic BI; Laurent G
Mol Pharmacol; 1995 Jan; 47(1):51-6. PubMed ID: 7838133
[TBL] [Abstract][Full Text] [Related]
31. Identification of a p53-dependent negative response element in the bcl-2 gene.
Miyashita T; Harigai M; Hanada M; Reed JC
Cancer Res; 1994 Jun; 54(12):3131-5. PubMed ID: 8205530
[TBL] [Abstract][Full Text] [Related]
32. Cloning and sequence analysis of the promoter region of the MRP gene of HL60 cells isolated for resistance to adriamycin.
Zhu Q; Center MS
Cancer Res; 1994 Aug; 54(16):4488-92. PubMed ID: 8044800
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
35. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
Mukhopadhyay T; Roth JA
Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
[TBL] [Abstract][Full Text] [Related]
36. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme.
Chen M; Beck WT
Cancer Res; 1993 Dec; 53(24):5946-53. PubMed ID: 8261408
[TBL] [Abstract][Full Text] [Related]
37. Regulation of insulin-like growth factor II P3 promotor by p53: a potential mechanism for tumorigenesis.
Zhang L; Kashanchi F; Zhan Q; Zhan S; Brady JN; Fornace AJ; Seth P; Helman LJ
Cancer Res; 1996 Mar; 56(6):1367-73. PubMed ID: 8640827
[TBL] [Abstract][Full Text] [Related]
38. Positive and negative regulatory elements in the murine p53 promoter.
Roy B; Reisman D
Oncogene; 1996 Dec; 13(11):2359-66. PubMed ID: 8957077
[TBL] [Abstract][Full Text] [Related]
39. Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM; Miller CW; Chen DL; Koeffler HP
Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
[TBL] [Abstract][Full Text] [Related]
40. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
Aloni-Grinstein R; Zan-Bar I; Alboum I; Goldfinger N; Rotter V
Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
